Blenrep, which is predicted by analysts to produce revenues of around $1.5bn in 2026, is an antibody-drug conjugate that works by targeting B-cell maturation antigen (BCMA), a protein commonly ...
The trial evaluated Blenrep (belantamab mafodotin), in combination with pomalidomide plus dexamethasone (PomDex), versus a standard of care, bortezomib plus PomDex. A pre-specified interim ...
While Blenrep has been granted accelerated approval by the FDA for multiple myeloma patients who have received at least four prior therapies – including an anti-CD38 monoclonal antibody, a ...
Hosted on MSN3mon
GSK Blenrep Combos for Multiple Myeloma Accepted for EU ReviewHowever, in November 2022, Blenrep was withdrawn from the U.S. market after the failure of GSK’s phase III confirmatory study, DREAMM-3, which evaluated Blenrep in patients with relapsed or ...
(Alliance News) - GSK PLC on Tuesday said its Blenrep cancer treatment will undergo review in Japan after successful authorisations recently in the UK and Europe. The London-based pharmaceutical ...
(Sharecast News) - Japan's health ministry has accepted for review a new drug application (NDA) for GSK's Blenrep blood cancer treatment, marking the third major regulatory filing acceptance for ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback